Psoriasis Comorbidities at Hospital Calderón Guardia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Psoriasis, Psoriasis Arthritis, Psoriasis (PsO), Psoriasis Patients. Basic parameters: from 12 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Costa Rica
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prevalence of Metabolic Comorbidities, Atherosclerotic Arterial Disease, and Psoriatic Arthritis in Patients With Psoriasis and Their Association With Clinical Severity and Therapeutic Profile Among Patients Treated at Hospital Rafael Ángel Calderón Guardia During 2024-2025
Overview
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are: What are the demographic and clinical characteristics and severity profiles of psoriasis patients? What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes? Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.
Detailed description
Psoriasis is a chronic immune-mediated inflammatory dermatosis with variable severity, systemic associations, and substantial quality-of-life impact. Although multiple topical, phototherapy, systemic, and biologic treatments are available, real-world epidemiologic and therapeutic data in Costa Rica remain limited. This study is a retrospective observational characterization of psoriasis patients treated between 2024 and 2025. Unlike interventional trials evaluating specific drugs or prospective registries of targeted therapies, this study analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI), comorbidities, and treatment patterns across routine care. It does not introduce therapeutic modifications or standardized follow-up, but reflects real-world management decisions across disease severities. By capturing population-level data on psoriasis presentation and treatment in Costa Rica, the study provides baseline national evidence distinct from drug-specific or interventional psoriasis studies.
Primary outcome measures
- Prevalence of Metabolic Comorbidities in Patients With Psoriasis [Time frame: 2024-2025]
- Prevalence of Atherosclerotic Cardiovascular Disease [Time frame: 2024-2025]
- Prevalence of Psoriatic Arthritis [Time frame: 2024-2025]
Secondary outcome measures (4)
- Psoriasis Severity [Time frame: 2024-2025]
- Psoriasis Severity [Time frame: 2024-2025]
- Association Between Psoriasis Severity and Comorbidities [Time frame: 2024-2025]
- Inflammatory and Metabolic Biomarkers [Time frame: 2024-2025]
Eligibility criteria
Inclusion criteria
- Patients evaluated in outpatient clinics during the period 2024-2025.
- Patients receiving systemic therapy and/or phototherapy.
- Patients aged 12 years or older, of any sex.
- Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.
- At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period.
- Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.
Exclusion criteria
- Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.
- Patients managed exclusively with topical therapies.
- Duplicate or inconsistent records, preventing accurate patient classification.
- Cutaneous conditions not compatible with psoriasis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Costa Rica · 1 center
- Caja Costarricense del Seguro Social — San José
Identifiers
NCT: NCT07448337 · CEC HCG 03-2026